Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?

Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed the broader equities market. However, the drugmaker may not be able to pull that off in 2025, because several setbacks this year have sunk its stock price. As of this writing, its shares are down 9% year to date, while the S&P 500 is up 9%.Lilly is on track for its worst annual performance in a long time, but does that mean investors should steer clear of the stock? Let's find out.In the second quarter, Eli Lilly once again posted financial results that made it the envy of its similarly sized peers. Revenue increased by 38% year over year to $15.6 billion, while adjusted earnings per share came in at $6.31, 61% higher than the year-ago period. Yet the company's shares fell. What gives?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool